Ligand Pharmaceuticals (LGND) EBIT Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 2,150.96% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 147.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.96% |
| Dec 31, 2025 | 243.64% |
| Sep 30, 2025 | 1,647.73% |
| Jun 30, 2025 | 144.21% |
| Mar 31, 2025 | -1,312.05% |
| Dec 31, 2024 | -186.99% |
| Sep 30, 2024 | 2.11% |
| Jun 30, 2024 | -863.19% |
| Mar 31, 2024 | -78.97% |
| Dec 31, 2023 | 83.29% |
| Sep 30, 2023 | -75.06% |
| Jun 30, 2023 | -122.89% |
| Mar 31, 2023 | 565.96% |
| Dec 31, 2022 | -153.33% |
| Sep 30, 2022 | -21.42% |
| Jun 30, 2022 | -81.06% |
| Mar 31, 2022 | -54.76% |
| Dec 31, 2021 | 64.84% |
| Sep 30, 2021 | 319.16% |
| Jun 30, 2021 | 544.21% |